Avantor, Inc. AVTR
Composite 35/100; the shares have moved about 47% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 9/100 — a strong mark against it.
Momentum ranks 70/100 — a moderate point in its favour.
Growth ranks 9/100 — a strong mark against it. Quality ranks 20/100 — a strong mark against it. Valuation ranks 35/100 — a moderate mark against it.
What the company does Avantor provides mission-critical products and services to biopharma, healthcare, and advanced-technology industries, including consumables (chemicals, lab supplies), equipment (filtration systems, freezers), and services (procurement, development). Its portfolio spans purity chemicals, single-use assemblies, and scientific support services.
Key financials Avantor’s profitability metrics are weak: ROE -9%, ROA 3%, ROCE -3%, net margin -8%, and EPS growth -33%. Gross margin is 32%, but operating and net margins are 6% and -8%, respectively. Debt/equity is 0.66, net debt/EBITDA 3.53, and interest coverage -1.58.
Stock health Momentum is mixed: +77% over 3 months, +25% over 6 months, but -1% over 12 months and -13% below its 52-week high. RSI(14) is 76, indicating overbought conditions. Sideravia scores the stock as “poor quality, fairly valued,” with overall 35/100 and valuation 54/100.
Price vs fair value AVTR trades at a **PREMIUM of 20.80%** to our fair-value estimate of 10.98 and a **discount of 5.08%** to the analyst 12-month target of 14.56. - Q2 earnings beat estimates and guidance was raised (Zacks, 2026-07-30). - Strategic initiatives and segment execution drove the outlook increase (StockStory, 2026-07-30). - One segment’s stabilization contributed to the stock surge (Trefis, 2026-07-30). - Golden cross signal flashed, suggesting technical momentum (Zacks, 2026-07-31).
Looking forward Forward P/E is 13.70, but PEG is n/a due to negative trailing earnings. FCF yield is 5.0%, and P/B is 1.40. Analysts (n=14) see potential upside to 14.56, balancing recent operational challenges with reported growth initiatives.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.